Precision BioSciences (DTIL)

• Market cap: $180M
• 1 day: -0.14%
• 5 days: -4.12%
• 1 month: -11.07%
• 3 months: -2.24%
• 6 months: 75.63%
• Year to date: 70.49%
• 1 year: 47.16%
• 5 years: -97.65%
• 10 years: -98.66%
• Sector: Healthcare
• Industry: Biotechnology

About: Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Employees: 66